Trial Profile

Phase II proof-of-concept study of andexanet alfa with betrixaban in volunteers

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Andexanet alfa (Primary)
Indications Haemorrhage
Focus Pharmacodynamics; Proof of concept
Sponsors Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals

Most Recent Events

06 Dec 2016 Results of Cohort 1 and 2 (n=18) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
07 Nov 2016 According to a Portola Pharmaceuticals media release, data from the study will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting 2016.
26 Feb 2016 According to a Portola Pharmaceuticals media release, the company plans to present data from this phase 2 proof-of-concept study of andexanet and betrixaban at a medical conference in 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com